Cargando…

Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease affecting multiple organ systems that runs an unpredictable course and may present with a wide variety of clinical manifestations. Advances in treatment over the last decades, such as use of corticosteroids and conventio...

Descripción completa

Detalles Bibliográficos
Autores principales: Samotij, Dominik, Reich, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668536/
https://www.ncbi.nlm.nih.gov/pubmed/31396534
http://dx.doi.org/10.1155/2019/8142368
_version_ 1783440235910135808
author Samotij, Dominik
Reich, Adam
author_facet Samotij, Dominik
Reich, Adam
author_sort Samotij, Dominik
collection PubMed
description Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease affecting multiple organ systems that runs an unpredictable course and may present with a wide variety of clinical manifestations. Advances in treatment over the last decades, such as use of corticosteroids and conventional immunosuppressive drugs, have improved life expectancy of SLE sufferers. Unfortunately, in many cases effective management of SLE is still related to severe drug-induced toxicity and contributes to organ function deterioration and infective complications, particularly among patients with refractory disease and/or lupus nephritis. Consequently, there is an unmet need for drugs with a better efficacy and safety profile. A range of different biologic agents have been proposed and subjected to clinical trials, particularly dedicated to this subset of patients whose disease is inadequately controlled by conventional treatment regimes. Unfortunately, most of these trials have given unsatisfactory results, with belimumab being the only targeted therapy approved for the treatment of SLE so far. Despite these pitfalls, several novel biologic agents targeting B cells, T cells, or cytokines are constantly being evaluated in clinical trials. It seems that they may enhance the therapeutic efficacy when combined with standard therapies. These efforts raise the hope that novel drugs for patients with refractory SLE may be available in the near future. This article reviews the current biological therapies being tested in the treatment of SLE.
format Online
Article
Text
id pubmed-6668536
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-66685362019-08-08 Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review Samotij, Dominik Reich, Adam Biomed Res Int Review Article Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease affecting multiple organ systems that runs an unpredictable course and may present with a wide variety of clinical manifestations. Advances in treatment over the last decades, such as use of corticosteroids and conventional immunosuppressive drugs, have improved life expectancy of SLE sufferers. Unfortunately, in many cases effective management of SLE is still related to severe drug-induced toxicity and contributes to organ function deterioration and infective complications, particularly among patients with refractory disease and/or lupus nephritis. Consequently, there is an unmet need for drugs with a better efficacy and safety profile. A range of different biologic agents have been proposed and subjected to clinical trials, particularly dedicated to this subset of patients whose disease is inadequately controlled by conventional treatment regimes. Unfortunately, most of these trials have given unsatisfactory results, with belimumab being the only targeted therapy approved for the treatment of SLE so far. Despite these pitfalls, several novel biologic agents targeting B cells, T cells, or cytokines are constantly being evaluated in clinical trials. It seems that they may enhance the therapeutic efficacy when combined with standard therapies. These efforts raise the hope that novel drugs for patients with refractory SLE may be available in the near future. This article reviews the current biological therapies being tested in the treatment of SLE. Hindawi 2019-07-18 /pmc/articles/PMC6668536/ /pubmed/31396534 http://dx.doi.org/10.1155/2019/8142368 Text en Copyright © 2019 Dominik Samotij and Adam Reich. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Samotij, Dominik
Reich, Adam
Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
title Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
title_full Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
title_fullStr Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
title_full_unstemmed Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
title_short Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
title_sort biologics in the treatment of lupus erythematosus: a critical literature review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668536/
https://www.ncbi.nlm.nih.gov/pubmed/31396534
http://dx.doi.org/10.1155/2019/8142368
work_keys_str_mv AT samotijdominik biologicsinthetreatmentoflupuserythematosusacriticalliteraturereview
AT reichadam biologicsinthetreatmentoflupuserythematosusacriticalliteraturereview